Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double‐blind, placebo‐controlled study

類似資料

• Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
  著者:: Durgam, Suresh, 等
  出版事項: (2018)
• A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
  著者:: Durgam, Suresh, 等
  出版事項: (2018)
• A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder
  著者:: Shiovitz, Thomas, 等
  出版事項: (2014)
• A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
  著者:: Gommoll, Carl P., 等
  出版事項: (2014)
• Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
  著者:: Montgomery, Stuart A., 等
  出版事項: (2014)